{"uid":"cap_3_IUFjNd_dcsOfq_Ox8pn","slug":"patentpulse-pharma-patent-cliff-analysis-91bc2550","name":"PatentPulse Pharma Patent Cliff Analysis","description":"Pharma patent cliff / drug patent expiry / generic-entry analysis by drug name (e.g. Humira, Ozempic). Returns the patent expiry calendar, exclusivity timeline, and generic/biosimilar entry outlook across US, EU, and Japan, plus related USPTO patents. For IP and investment agents. Worldwide.","url":"https://patentpulse-self.vercel.app/api/patent/cliff","method":"GET","headers":{},"bodySchema":{"type":"object","required":["drug"],"properties":{"drug":{"type":"string","description":"Drug name — generic or brand (e.g. humira, ozempic, keytruda)"},"lang":{"type":"string","description":"Response language"}}},"responseSchema":{"type":"json","example":{}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.15","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.15/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.15","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.15","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_vQIHQ3lRKYaJkICf4Jh09","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.15","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns a drug patent expiry calendar and generic-entry analysis for pharma patent cliff intelligence.","exampleAgentPrompt":"Pull the patent cliff analysis for top-selling GLP-1 drugs like Ozempic and Wegovy — I need the expiry calendar and generic entry windows over the next 5 years for an investment memo.","exampleUseCases":[{"title":"Assess patent cliff risk for portfolio","prompt":"Can you run a patent expiry analysis for our top 10 pharma holdings? I need the exclusivity timelines and generic entry dates for each drug so we can model revenue impact and identify which positions face the biggest cliff risk in the next 5 years."},{"title":"Plan generic manufacturing entry strategy","prompt":"Show me the patent expiration calendar for leading autoimmune and rheumatology drugs — Humira, Rinvoq, Skyrizi — with their exclusivity windows and expected generic/biosimilar entry dates. We're evaluating which therapeutic areas to prioritize for our generic pipeline."},{"title":"Track oncology drug exclusivity windows","prompt":"Pull the patent cliff data for our oncology franchise including Keytruda, Opdivo, and Tecentriq. I need the expiration dates, remaining exclusivity periods, and expected generic entry timelines across the US, EU, and Japan for our business development strategy."}],"resultDescription":"Returns a structured patent expiry calendar including drug names, patent expiration dates, exclusivity end dates, generic entry timelines, and revenue-at-risk indicators for specified drugs or therapeutic categories.","failureModes":["Drug or compound not found in patent database — returns empty result or 404","Invalid query parameters — returns 400 with parameter validation error","Patent data temporarily unavailable for a jurisdiction — partial result with warning","Payment not processed — returns 402 payment required","Rate limit exceeded — returns 429 with retry-after header"],"whenToPreferThis":"Use this endpoint when you need pharma-specific patent cliff intelligence — expiry calendars, generic entry timelines, and exclusivity windows — for IP strategy, investment analysis, or business development decisions in the pharmaceutical space. Prefer this over general patent search endpoints when the core question is about when a drug loses protection and generic competition begins.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T12:49:25.348Z","isFirstParty":false}